Adolescent and young adult (age 14-22) usage of "Gas Station" substances of abuse in South Carolina: a demographic survey

Date Added
March 30th, 2026
PRO Number
Pro00149239
Researcher
Katie Sahlstrom

List of Studies

Keywords
Adolescents, Mental Health, Substance Use
Summary

Quantitative survey of certain substances of abuse in the adolescent and young adult population of SC. Survey study will be focused on substances of abuse that are easily accessible at a gas station due to little to no regulations or excessive amounts available in various forms such as Kratom, 7-OH, Tia, nicotine pouches, THC, etc.

Institution
Self Regional Healthcare
Recruitment Contact
Katie Sahlstrom
9182938920
katie.sahlstrom@selfregional.org

Optimizing Clinical Screening for Body Image Distress Among Head and Neck Cancer Survivors: Implementation of a Short Form of the IMAGE-HN Questionnaire

Date Added
March 24th, 2026
PRO Number
Pro00149346
Researcher
Haley Hullfish

List of Studies

Keywords
Cancer/Head & Neck
Summary

This study is designed to improve how body image distress is identified among adult survivors of head and neck cancer during routine clinic visits. Participants will complete questionnaires about body image concerns either on paper or electronically (in clinic or remotely through a secure link). The study will evaluate how well a brief screening questionnaire (IMAGE-HN SF) identifies patients experiencing meaningful body image distress compared with the longer, full IMAGE-HN survey. In addition to assessing how accurately the short form performs, we will ask patients how they prefer the screening to be delivered, including the timing, format, and method of completion in routine care. A subset of participants will be invited to complete a short interview to share additional thoughts about how this type of screening should be implemented. Findings from this study will help guide the use of efficient and patient-centered body image screening in head and neck cancer clinics.

Institution
MUSC
Recruitment Contact
Haley Hullfish
843-278-3842
hullfish@musc.edu

Prospective Observational Study on the Natural History of Alpha-1 Antitrypsin Deficiency and Associated Liver Disease (ALPHATUDE)

Date Added
March 20th, 2026
PRO Number
Pro00147215
Researcher
Charlie Strange

List of Studies


Keywords
Liver, Lung, Pulmonary, Rare Diseases
Summary

This an observational study collecting data for up to 8 years on patients who have been diagnosed with PiZZ or PiSZ Alpha-1 Antitrypsin Deficiency with or without liver disease. Patients' clinical, medical, and laboratory data will be collected prospectively per routine care and questionnaires will be collected during the clinic visits with the hopes of getting a better understanding of the natural progress of lung and liver disease associated with Alpha-1 Antitrypsin Deficiency.

Institution
MUSC
Recruitment Contact
Gwen Hayden
843-792-8438
blantonm@musc.edu

A Descriptive Study Assessing Sexual Activity Following Sacrocolpopexy

Date Added
March 19th, 2026
PRO Number
Pro00148799
Researcher
Addison McFarland

List of Studies

Keywords
Sexual Dysfunction, Women's Health
Summary

This is a descriptive study designed to determine the proportion of women who are sexually active after minimally invasive sacrocolpopexy, with particular focus on those aged 65 and older. Because sacrocolpopexy carries certain risks—especially in older women—but also preserves vaginal length and may improve sexual function, understanding post-surgical sexual activity can help clinicians counsel patients when choosing between reconstructive surgeries, which preserve vaginal length, and obliterative surgeries, which do not. The study also aims to better understand patient values in surgical decision-making related to sexual activity. Women who had sacrocolpopexy at MUSC since January 1, 2015 will be contacted to complete two questionnaires: one assessing sexual activity and satisfaction with surgery, and one assessing sexual function using an adapted PISQ-IR questionnaire. Data will be analyzed using descriptive and comparative statistics to examine the proportion of sexually active women in groups under 65 versus 65 and older, as well as to compare their sexual function outcomes.

Institution
MUSC
Recruitment Contact
Addison McFarland
312-282-5522
mcfaradd@musc.edu

PRIMary care Engagement in Survivorship (PRIMES): A Mixed Methods Study

Date Added
March 18th, 2026
PRO Number
Pro00149836
Researcher
Michelle Mollica

List of Studies


Keywords
Cancer/Gastrointestinal, Healthy Volunteer Studies, Non-interventional
Summary

This study aims to improve cancer survivorship care work by refining how primary care providers and cancer specialists share responsibilities. Researchers want to understand how technology can help these teams communicate more clearly and effectively to coordinate care for survivors. The study team will use surveys, conduct interviews and organize focus groups for interested and eligible participants as methods of data collection to inform the research. Oncologists, Primary Care Physicians, administrative leads and colon or rectal cancer survivors that meet the eligibility criteria will complete surveys, engage in interviews and group discussions from each perspective to learn strategies to improve care, including who should handle which parts of survivorship care. Using this information, the team will create an intervention plan called PRIMES that outlines strategies to overcome common barriers. The ultimate goal is to help survivors receive better and more coordinated follow‑up care.

Institution
MUSC
Recruitment Contact
Mary Chris Pittman
843-792-3512
pittmama@musc.edu

The Effect of Preoperative Cryotherapy on Pain, Opioid Use, and Early Functional Outcomes Following Anterior Cruciate Ligament Reconstruction

Date Added
March 17th, 2026
PRO Number
Pro00149208
Researcher
Thomas Moran

List of Studies

Keywords
Surgery
Summary

This study will evaluate whether using cold therapy before Anterior Cruciate Ligament (ACL) reconstruction surgery improves recovery during the first six weeks after surgery. Patients undergoing ACL reconstruction will either receive standard preoperative care or standard care plus a period of cold therapy prior to surgery. Pain levels, swelling, medication use, and functional recovery will be tracked using surveys and routine clinical follow-up information. participation will not change the surgical procedure or postoperative rehabilitation plan.

Institution
MUSC
Recruitment Contact
Katie Kessler
9195345432
kesslkat@musc.edu

Omission of Post-Operative Radiation in Patients with Intermediate Pathological Risk Features and Negative Two Week Post-Operative ctHPVDNA (OPERATION Trial)

Date Added
March 17th, 2026
PRO Number
Pro00149196
Researcher
Bhishamjit Chera

List of Studies

Keywords
Cancer
Summary

This study is for adult patients with Oral Squamous Cell Carcinoma (OSCC). The purpose of this study is to use results from a CLIA regulated blood test (NavDx) to measure tumor DNA to omit postoperative radiotherapy following surgery. Participation will include standard of care visits along with questionnaires and blood draws completed for research purposes. Participation in this study is anticipated to last approximately 2 years with a 3 year follow up period.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinicaltrials@musc.edu

Phase 4, Randomized, Double-Blind, Multicenter, Placebo Controlled, Parallel-Group Study of the Efficacy and Safety of SPN-812 in Preschool-Age Children (4 to 5 years old) with Attention-Deficit/Hyperactivity Disorder (ADHD)

Date Added
March 11th, 2026
PRO Number
Pro00146607
Researcher
Stephen Stripling

List of Studies

Keywords
ADD/ADHD, Children's Health
Summary

This is a randomized, double-blind, placebo-controlled, multicenter, 2-arm (1:1), parallel group, efficacy, and safety/tolerability fixed-dose study of SPN-812 in preschool-age children (4 to 5 years old) with a DSM-IV-TR diagnosis of ADHD. Approximately 286 subjects will be randomized to either SPN-812 or matching placebo in a 1:1 ratio (143 subjects per arm). Following up to 4 weeks of screening, subjects will be treated with study medication (SM) for 6 weeks, then will either be enrolled in a separate OLE study or followed for an additional 1 week for safety. The total duration of the study is up to 10 weeks.

Institution
MUSC
Recruitment Contact
Sydney Horton
843.473.6616
syh206@musc.edu

A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T-Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)

Date Added
March 10th, 2026
PRO Number
Pro00149742
Researcher
Ashwath Gurumurthi

List of Studies

Keywords
Cancer, Drug Studies, Men's Health, Women's Health
Summary

This phase III trial compares the effectiveness of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial chemotherapy. Participants will be separated into two groups, or randomized (like flipping a coin). The first group of participants will receive high dose chemotherapy followed by an autologous stem cell transplant. Giving chemotherapy before a stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. Stem cells removed prior to treatment are then returned to the patient to replace the blood forming cells that were destroyed by the chemotherapy. The second group will be observed by the study doctor and study team with check-ins every six months for 12 years after joining the trial. The group of participants who receive a stem cell transplant will also be checked by their doctor and study team for every 6 months for 12 years after joining the study. The main risks of the study treatment include reduced blood cell counts, nausea and vomiting, and damage to other organs (due to high dose chemotherapy).

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinicaltrials@musc.edu

A Phase 2, multinational, multicenter, randomized, doubleblind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe ulcerative colitis

Date Added
March 10th, 2026
PRO Number
Pro00149612
Researcher
Erin Forster

List of Studies


Keywords
Crohn's Disease, Digestive System
Summary

The study aims to evaluate if an experimental drug called SAR441566 can improve signs and symptoms of moderate to severe ulcerative colitis (UC). SAR441566 is a new drug that inhibits Tumor necrosis factor receptor 1 (TNFR1) signaling. This study will also help the Sponsor to understand which dose of SAR441566 is most effective and safe in participants with moderate to severe UC. To do this, 3 different doses of SAR441566 will be tested along with a placebo. The study will last about 1 year, will include about 260 adult participants across over 26 countries.

Institution
MUSC
Recruitment Contact
Zerlinna Teague
8437921221
recruitment@musc.edu



-- OR --